PURPOSE: Animal data suggest that the synthetic drug ecstasy may damage brain serotonin neurons. Previously we reported protracted reductions in the availability of the serotonin transporter (SERT), an index of integrity of the axon terminals of brain serotonergic neurons, in SERT-rich brain regions in current human ecstasy users. Comparison of current ecstasy users and former ecstasy users yielded some evidence that this reduction might be reversible. However, participant selection effects could not be ruled out. Therefore, follow-up examinations were performed in these subjects to test the following a priori hypothesis in a prospective longitudinal design that eliminates participant selection effects to a large extent: availability of the SERT increases towards normal levels when ecstasy use is stopped, and remains unchanged or is further decreased if use is continued. METHODS: Two follow-up positron emission tomography measurements using the SERT ligand [11C](+)McN5652 were completed by 15 current and nine former ecstasy users. All subjects used illicit drugs other than ecstasy, too. The time interval between repeated measurements was about 1 year. The time course of the availability of the SERT was analysed in the following SERT-rich regions: mesencephalon, putamen, caudate and thalamus. RESULTS: Current ecstasy users showed a consistent increase in the availability of the SERT in the mesencephalon during the study (Friedman test: p = 0.010), which most likely was caused by a decrease in the intensity of ecstasy consumption (Spearman correlation coefficient -0.725, p = 0.002). Former ecstasy users showed a consistent increase in SERT availability in the thalamus (Friedman test: p = 0.006). CONCLUSION: Ecstasy-induced protracted alterations in the availability of the SERT might be reversible.
PURPOSE: Animal data suggest that the synthetic drug ecstasy may damage brain serotonin neurons. Previously we reported protracted reductions in the availability of the serotonin transporter (SERT), an index of integrity of the axon terminals of brain serotonergic neurons, in SERT-rich brain regions in current humanecstasy users. Comparison of current ecstasy users and former ecstasy users yielded some evidence that this reduction might be reversible. However, participant selection effects could not be ruled out. Therefore, follow-up examinations were performed in these subjects to test the following a priori hypothesis in a prospective longitudinal design that eliminates participant selection effects to a large extent: availability of the SERT increases towards normal levels when ecstasy use is stopped, and remains unchanged or is further decreased if use is continued. METHODS: Two follow-up positron emission tomography measurements using the SERT ligand [11C](+)McN5652 were completed by 15 current and nine former ecstasy users. All subjects used illicit drugs other than ecstasy, too. The time interval between repeated measurements was about 1 year. The time course of the availability of the SERT was analysed in the following SERT-rich regions: mesencephalon, putamen, caudate and thalamus. RESULTS: Current ecstasy users showed a consistent increase in the availability of the SERT in the mesencephalon during the study (Friedman test: p = 0.010), which most likely was caused by a decrease in the intensity of ecstasy consumption (Spearman correlation coefficient -0.725, p = 0.002). Former ecstasy users showed a consistent increase in SERT availability in the thalamus (Friedman test: p = 0.006). CONCLUSION:Ecstasy-induced protracted alterations in the availability of the SERT might be reversible.
Authors: R V Parsey; L S Kegeles; D R Hwang; N Simpson; A Abi-Dargham; O Mawlawi; M Slifstein; R L Van Heertum; J J Mann; M Laruelle Journal: J Nucl Med Date: 2000-09 Impact factor: 10.057
Authors: N D Volkow; L Chang; G J Wang; J S Fowler; D Franceschi; M Sedler; S J Gatley; E Miller; R Hitzemann; Y S Ding; J Logan Journal: J Neurosci Date: 2001-12-01 Impact factor: 6.167
Authors: U Scheffel; Z Szabo; W B Mathews; P A Finley; R F Dannals; H T Ravert; K Szabo; J Yuan; G A Ricaurte Journal: Synapse Date: 1998-06 Impact factor: 2.562
Authors: Stephen J Kish; Jason Lerch; Yoshiaki Furukawa; Junchao Tong; Tina McCluskey; Diana Wilkins; Sylvain Houle; Jeffrey Meyer; Emanuela Mundo; Alan A Wilson; Pablo M Rusjan; Jean A Saint-Cyr; Mark Guttman; D Louis Collins; Colin Shapiro; Jerry J Warsh; Isabelle Boileau Journal: Brain Date: 2010-05-17 Impact factor: 13.501
Authors: Matthew L Banks; Paul W Czoty; H Donald Gage; Michael C Bounds; Pradeep K Garg; Sudha Garg; Michael A Nader Journal: Neuropsychopharmacology Date: 2007-04-18 Impact factor: 7.853
Authors: Simon N Young; Martine Regoli; Marco Leyton; Robert O Pihl; Chawki Benkelfat Journal: Psychopharmacology (Berl) Date: 2013-10-19 Impact factor: 4.530